A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC

Korábbi kezelés

• Adverse reactions caused by previous treatments.
• History of severe arterial-venous thrombosis within 3 months prior to the first administration.
• History of severe infection within 4 weeks prior to the first administration.

Más betegség

• History of other primary solid tumors.
• Severe, uncontrolled or active cardiovascular or cerebrovascular diseases.
• Severe or uncontrolled diabetes or hypertension.
• Clinically significant hemorrhage symptoms or significant hemorrhagic tendency.
• Active autoimmune diseases or active infectious diseases.
• History of severe neurological or mental disorders.
• Hepatic encephalopathy, hepatorenal syndrome, or ≥ Child-Pugh class B cirrhosis.
• Any condition that probably endangers the safety of the participants or interferes with the study assessment.

Egyéb

• Uncontrolled pleural effusion or peritoneal effusion.
• Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.

• Be willing to participate in this clinical trial with understanding of study procedures, ability to provide written informed consent.
• Men or women aged more than or equal to (≥) 18 years.
• At least one extra-cranial measurable lesion according to RECIST 1.1.
• Histologically or cytologically diagnosed as ES-SCLC.
• Adequate organ function.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0~1.
• Life expectancy >= 12 weeks.
• Men or women should be using adequate contraceptive measures throughout the study.
• Female participants with negative serum pregnancy test result within 7 days prior to first dose administration, or documentation of no pregnancy risk.